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Dendritic cellsDriven by constantly increasing knowledge about skin immunology, vaccine delivery via the cutaneous route
has recently gained renewed interest. Considering its richness in immunocompetent cells, targeting antigens
to the skin is considered to be more effective than intramuscular or subcutaneous injections. However, cir-
cumvention of the superﬁcial layer of the skin, the stratum corneum, represents the major challenge for cu-
taneous immunization. An optimal delivery method has to be effective and reliable, but also highly adaptable
to speciﬁc demands, should avoid the use of hypodermic needles and the requirement of specially trained
healthcare workers. The P.L.E.A.S.E.® (Precise Laser Epidermal System) device employed in this study for cre-
ation of aqueous micropores in the skin fulﬁlls these prerequisites by combining the precision of its laser
scanning technology with the ﬂexibility to vary the number, density and the depth of the micropores in a
user-friendly manner. We investigated the potential of transcutaneous immunization via laser-generated mi-
cropores for induction of speciﬁc immune responses and compared the outcomes to conventional subcutane-
ous injection. By targeting different layers of the skin we were able to bias polarization of T cells, which could
be modulated by addition of adjuvants. The P.L.E.A.S.E.® device represents a highly effective and versatile
platform for transcutaneous vaccination.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Most vaccines are administered tomuscle or subcutaneous tissue by
injection using needle and syringe. Whereas the transcutaneous route
was heavily employed during the smallpox eradication campaign
by scariﬁcation with a bifurcated needle [1], currently only Bacille
Calmette Guérin vaccine against tuberculosis and rabies vaccine in
developing countries are delivered intradermally [2,3]. For both, the
Mantoux method is used, which employs a conventional hypodermic
needle inserted at a shallow angle into the skin. Invented by Mendel &
Mantoux in the early 1900s [4], this technique requires well-trained
healthcare personnel to achieve consistent delivery [5,6] and also in-
volves the general disadvantages associatedwith the use of hypodermic
needles, including pain and apprehension felt especially by children,
needlestick injuries, and intentional re-use of needle and/or syringe.
The latter two are responsible for more than half a million deaths annu-
ally due to transmission of HIV and hepatitis B and C [7].x: 43 662 8044 5751.
mer).
-NC-ND license.In contrast to muscle, which cannot be considered a highly immuno-
genic organ [8], the skin represents an attractive target tissue for vaccina-
tion due to its high accessibility and its unique immunologic properties.
The epidermis and dermis are rich in immunocompetent cells, which
mediate the immune response following skin immunization [9–13].
Langerhans cells (LCs) and dermal dendritic cells (DCs) residing in the
epidermal and the dermal compartment of the skin, respectively, are
key players in skin immune responses. They capture, process, and pre-
sent foreign antigen, and closely interplay with keratinocytes, mast
cells and T lymphocytes [14,15]. Among the other cells in the epidermis
and dermis, skin keratinocytes, in particular, have the potential to
enhance and shape immune responses by producing cytokines and
chemokines [12]. Compared to intramuscular injection, vaccination via
the skin results in more efﬁcient antigen trafﬁcking into lymph nodes
(LNs) [16–18].
The efﬁcacy of skin vaccination has been recently demonstrated
by several clinical studies [19], among them some showing compara-
ble results at lower dosage [20–22], improved protection in elderly
persons [23,24], or mucosal immunity [10,25,26].
Many vaccines could become candidates for delivery via the skin if
an easily applicable, reliable, patient-friendly immunization method
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is to overcome the superﬁcial layer of the skin, the stratum corneum,
which acts as an almost impermeable barrier, preventing diffusion of
molecules, particularly those of a molecular weight beyond 500 Da
[27]. A variety of non- or minimally invasive methods to enhance
transcutaneous antigen delivery have been developed, including liq-
uid jet injection, epidermal powder immunization, tape stripping,
skin abrasion, thermal ablation, ultrasound, tattooing, and the use of
arrays of solid, coated, hollow or dissolvable microneedles, as
reviewed by Bal et al. [28]. However, the skin is a heterogenous tissue
and its properties highly depend on body location, age, skin type, hy-
dration level, and body weight, and also vary between individuals
[29]. Therefore, introduction of a methodology to circumvent the
stratum corneum in a reproducible, but also highly adaptable manner
would be desirable.
The P.L.E.A.S.E.® (Precise Laser Epidermal System) device developed
by Pantec Biosolutions offers the opportunity to create aqueous micro-
pores of approximately 150 μm diameter via controlled fractional abla-
tion of skin layers. This novel technique employs a diode-pumped
Erbium:yttrium-aluminium-garnet (ER: YAG) laser, which emits ener-
gy at 2.94 μm — a major absorption wavelength of water molecules.
Their excitation and evaporation leads to formation of pores ﬁlled
with exudate, without causing thermal damage to adjacent skin tissue.
The number of micropores to be created can be varied by the user as
well as the laser ﬂuence (energy per unit area) determining the depth
of the micropores. This allows for selective targeting of different skin
layers, rendering the P.L.E.A.S.E.® device adjustable to speciﬁc needs.
The high pulse repetition rate of up to 1 kHz enables sequential creation
of an array of several hundredmicropores within a few seconds [30,31].
Inmost previous studies using ER: YAG lasers to circumvent the skin
barrier, devices with a single laser beam and a ﬁxed spot diameter of
several millimeters have been employed [32–41]. Compared to frac-
tional ablative systems, these devices remove a much larger amount
of skin surface leading to a prolonged healing time. More recently, con-
ventional fractional ER: YAG lasers have been employed, which create a
micropore grid in the skin requiringmanual adjustment to create addi-
tional pores [39,40], or which split the laser beam into separate beams
using a grid to fractionate the energy [41]. In contrast, the P.L.E.A.S.E.®
device uses a beamdeﬂection unit that can generate any number of pre-
cise pores in an area with a diameter of up to 3 cm.
It has been demonstrated that laser microporation using the
P.L.E.A.S.E.® device signiﬁcantly increased in vitro transport of lowmo-
lecularweight compounds [30,31,42], and also enableddelivery of func-
tional antibodies through porcine, murine and human skin samples as
well as throughmurine skin in vivo [43]. Moreover, in vivo laser micro-
poration followed by delivery of follicle stimulating hormone for super-
ovulation has been reported [44].
Very recently, delivery of drugs or ovalbumin as model antigen via
microchannels generated by fractional ablation of the skin was demon-
strated to be superior in comparison to tape stripping [45]. In our current
paperwedemonstrate for theﬁrst time the use of the P.L.E.A.S.E.® device
for transcutaneous immunization (TCI) with protein antigens and pro-
vide an in-depth characterization of the resulting immune responses.
2. Materials and methods
2.1. Mice and immunizations
BALB/c and C57BL/6 females aged 6–8 weeks were purchased
from Charles River Laboratories (Sulzfeld, Germany), DO11.10,
OT-II, OT-I, C57BL/6 and BALB/c expressing the CD45.1 alloantigen,
and Lang-DTR-enhanced GFP (Lang-DTR) [46] backcrossed for
more than 9 generations onto C57BL/6 or BALB/c backgrounds, re-
spectively, were bred and maintained at the animal facility of the
University of Salzburg and used at an age of 6–12 weeks. Ovalbumin
(OVA) transgenic mice were crossed with CD45.1 BALB/c or C57BL/6mice and the F1 generation was used as donors for transfer experiments.
Animal experiments were conducted according to local guidelines ap-
proved by the Austrian Ministry of Science (Permit Number: GZ 66.012/
0004-II/10b/2010). The day before laser microporation, animals were
shaved on their back with a clipper and depilatory creamwas used to re-
move residual hair. Laser microporation using the P.L.E.A.S.E.® device
(Pantec Biosolutions) was performed by placing anesthetized mice with
their back at the focal length of the laser. Poration parameters, i.e. number
of pores/cm2, number of pulses per pore, and ﬂuence (energy applied per
unit area) were pre-programmed using the device software and are indi-
cated for each experiment. If not stated otherwise, the respective antigens
were applied as aqueous solution to themicroporated skin area and left to
completely dry.
2.2. Antigens
FITC-Dextran (MW: 2000 kDa), ovalbumin (OVA, grade V), beta-
galactosidase (bGal), bovine serum albumin (BSA), and FITC were pur-
chased from Sigma–Aldrich (Deisenhofen, Germany). FITC-BSAwas pre-
pared according to the protocol supplied by Sigma. Recombinant Phl p 5,
a major grass pollen allergen with aMWof 38 kDa, was purchased from
Biomay AG, Vienna, Austria.
2.3. Histological analysis
2 μm parafﬁn sections of skin samples were prepared and stained
with haematoxylin/eosin using standard methods.
For ﬂuorescence microscopy, microporated skin samples were em-
bedded in Tissue-Tek® O.C.T. ™ compound in Tissue-Tek cryomolds
(Sakura Fintek Europe B.V., Alphen aan den Rijn, Netherlands), gently
frozen, and stored at −70 °C until preparation of frozen sections
(10 μm), which were mounted on microscopic slides, embedded in
Mowiol and analyzed on a ﬂuorescence microscope (Olympus IX70).
For scanning electron microscopy, samples were ﬁxed for 2 h with
Karnovsky [47], postﬁxation was performed with 1% osmium tetroxide
( buffered at pH 6.5 with 0.1 M sodium cacodylate ) for further 2 h. The
postﬁxed sampleswere dehydrated in an ascending series of ethyl alco-
hol, critical-point-dried, and subsequently sputteredwith gold (~ 5 nm)
and analyzed in an environmental scanning electron microscope, ESEM
XL30 (FEI, Philips, Eindhoven, the Netherlands), operating at 20 kV.
2.4. Transcutaneous delivery through porcine skin
Dermatomed porcine ear skin (thickness: 0.75 mm) was
porated at 900 pores/30 pulses per pore. Following poration, the
skin samples were mounted in Franz diffusion cells with a
cross-sectional area of 2.9 cm2. 1 mL of unbuffered FITC-BSA
(MW ~70 kDa) solution (10 mg/mL) was placed in the donor com-
partment. Tris buffer (pH 7.4) was used as receptor solution and
samples of 3 mL thereof were taken after 24 h to determine perme-
ation via measurement of ﬂuorescence at λex496 nm and λem500–
650 nm. By soaking the skin samples in 6 mL of a suitable extrac-
tion medium for 4 h followed by ﬁltration through PVDF mem-
branes (0.45 μm), the amount of FITC-BSA deposited in the skin
was determined.
2.5. Flow cytometric analysis of DLN-DCs
BALB/c mice (n=4) were laser microporated at a ﬂuence of
0.76 J/cm2 per pulse, generating an array of 1600 pores with a diam-
eter of 2 cm applying either 1 or 8 pulses per pore. 100 μl of
FITC-dextran in PBS [10 mg/ml] was topically administered, or was
s.c. injected. After 72 h, cells from axillary and inguinal LNswere pre-
pared [48], pooled for each group, and surface stained with
anti-MHC-II (clone M5/114, BD Pharmingen), anti-CD11b (clone
M1/70, BioLegend), anti-CD103 (clone M290, BD Pharmingen),
Fig. 1. Histological analysis of laser-generated micropores in mouse skin. A) Top view of
skin after laserporation using 2 pulses (F=1.9 J/cm2 per pulse), 400 pores/cm2. Panels
B–D show representative HE-stained parafﬁn skin sections displaying a single pore after
laserporation with 1 (B), 4 (C), or 8 pulses (D) delivered at 1.9 J/cm2 per pulse. Panel E
shows a SEM picture of a single pore generated by delivery of 8 pulses at 0.76 J/cm2 per
pulse.
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929F3; Dendritics-AbCys). Cells were recorded on a FACSCanto II
ﬂow cytometer and analyzed using FACSDiva Software (BD
Biosciences).
2.6. In vivo proliferation and characterization of OVA transgenic T cells
For in vivo proliferation assays, on day 0, 2×106 splenocytes from
OT-II, OT-I, or DO.11.10 donors (CD45.1 background) were labelled
with a Vybrant CFDA SE Cell Tracer Kit (CFSE, Life Technologies)
and adoptively transferred to naive recipient mice as described
[48]. OVA was applied to laser microporated skin (900 pores,
1.5 cm diameter, 6 pulses delivered at 1.9 J/cm2 per pulse) on day
1 and was completely absorbed within 10–20 min. 6 days later,
DLN cells were prepared and proliferation was assessed by gating
on CD45.1+ CD4+ (CD8+ in case of OT-I) cells and calculating
the proliferation index (proliferated/non-proliferated cells). In
some groups, Langerin+ cells were ablated by i.p. injection of 1 μg
diphtheria toxin (DT) on days−1, 2, and 5.
Proliferated vs. non-proliferated DO11.10 T cells were further ana-
lyzed by surface staining with anti-CD134 (clone OX-86, eBioscience),
anti-CD62L (clone MEL-14, eBioscience), anti-CD45RB (clone C363.16A,
eBioscience), anti-Tim-1 (RMT1-4, eBioscience), anti-Tim-3 (RMT3-23,
eBioscience), anti-CD25 (clone PC61, BD Pahrmingen), anti-CD152
(clone UC10-4B9, eBioscience), and intracellular staining with anti-T-bet
(clone eBio4B10, eBioscience), anti-Gata-3 (clone TWAJ, eBioscience),
and anti-FoxP3 (clone FJK-16 s, eBioscience), after application of 100 μg
OVA distributed between two non-overlapping microporated areas
(400 pores, 1 cm diameter, 1–6 pulses delivered at 1.9 J/cm2 per pulse),
or a respective s.c. injection. 10,000 splenocytes per mouse from these
groups were cultured in vitro together with 100,000 X-ray irradiated at
a dose of 60 Gy (80 kV, 16 mA) syngeneic feeder cells in the presence
of 20 μg/mL OVA for 3 days and culture supernatants were analyzed for
cytokine secretion using FlowCytomix Multiplex kits (eBioscience)
according to the manufacturers protocol.
2.7. Characterization of endogenous immune responses
BALB/c LangDTRmicewere immunized by applying 200 μgOVAdis-
tributed between two non-overlappingmicroporated areas (400 pores,
1 cm diameter, 6 pulses delivered at 0.76 J/cm2 per pulse) on days
0 and 7. One group was injected i.p. with 1 μg DT on day −1. Mice
were sacriﬁced on day 14, when blood samples were drawn and
splenocytes were harvested. Antibody levels in sera were measured
by a luminometric ELISA assay at indicated serumdilutions lyingwithin
the linear range of the assay. Biologically functional IgE was assessed by
an in vitro basophil release assay. Splenocytes were cultured without
feeder cells and cytokines were measured as described above. A more
detailed description of these assays can be found elsewhere [49].
Immunization of BALB/c mice (n=3) with beta-galactosidase
was performed by applying 5 μg of protein on days 0 and 11, and
10 μg of protein on day 31 on microporated skin (1500 pores,
2.5 cm diameter, 8 pulses delivered at 1.9 J/cm2 per pulse) with or
without TLR agonists poly I:C (Sigma), R848 (Alexis), or pho-
sophothioate CpG ODN1826 (Biomers) at the indicated doses ap-
plied in PBS or PBS/36% DMSO (only R848 groups). Sera were
analyzed for IgE via in vitro basophil release assay on day 44 and
splenocytes were analyzed for IL-4 and IFN-γ secretion by ELISPOT
assay as described [48].
To assess immune responses against Phl p 5, BALB/c mice (n=5)
were immunized on days 0 and 10 with 5 μg Phl p 5 applied to micro-
porated skin (400 pores, 1 cm diameter, 4 pulses delivered at 1.9 J/
cm2 per pulse) with or without 100 μg ODN1826 or via s.c. injection
of the same dose. Sera taken at day 28 were analyzed by luminometric
ELISA and in vitro basophil release assay.2.8. Statistical analysis
Statistical signiﬁcance between groups was assessed by unpaired
Students T-Test (alpha=.05) using SigmaStat 2.0. Groups that failed
normality test were compared using Mann–Whitney rank sum test.3. Results
3.1. Targeting of different skin layers
Transcutaneous application of macromolecules via laser-generated
micropores using the P.L.E.A.S.E® device has been previously demon-
strated in vitro for porcine as well as human skin [43]. To evaluate the
immune responses generated by transcutaneous vaccination we ﬁrst
established the optimal laser parameters for mouse skin. Fig. 1A
shows an array of 400 laser-generated micropores per cm2 in the skin
of a BALB/cmouse. Bymodulating the number of pulses per pore, differ-
ent skin depths can be targeted. At low pulse numbers, the stratum cor-
neum is weakened and partly removed, while the epidermis stays
mainly intact (Fig. 1B). By increasing the pulse number, the epidermis
is removed, exposing the underlying dermis (Fig. 1C), which can be
Fig. 2. In vivo uptake of FITC-BSA via laser-generated micropores in mouse skin. A
5 mm×5 mm piece of gauze was soaked with 80 μL of FITC-labeled BSA (10 mg/mL),
applied to laser-generated micropores and covered with Tegaderm™. At different
time points, skin areas were excised, embedded in Tissue-Tek® O.C.T.™ compound,
and frozen sections (10 μM) were prepared. Fluorescence microscopy revealed that
FITC-BSA speciﬁcally attaches to micropores, recognizable as indentations in the skin
(indicated by arrows), from where it slowly diffuses into deeper skin layers. After
4 days, a residual depot is still discernable.
Fig. 3. Analysis of DCs in skin DLNs 72 h after application of FITC-dextran to laser
porated mouse skin. A) Gating of MHC-IIhigh DCs (left), separation into Langerin pos-
itive and negative DCs (middle), and quantitation of FITC-dextran positive cells (right).
B) Percentage of MHC-IIhigh DCs in DLNs which have taken up FITC-dextran after
laserporation with 1 pulse or 8 pulses or after subcutaneous injection. C) DC subclass
distribution in DLNs after laserporation and subcutaneous injection. D) DC subclass
distribution of FITC-dextran positive DCs in DLNs. Data are shown for pooled samples
of three BALB/c mice per group.
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of 1.9 J/cm2 per pulse, no carbonization takes place, enabling high diffu-
sion rates via aqueous micropores (Fig. 1E).
When applying FITC-labeled BSA to microporated skin, the
antigen selectively attaches to the surface of the micropores from
where it slowly diffuses into deeper layers of the skin (Fig. 2). In
vitro experiments with porcine skin samples have shown that
FITC-BSA (10 mg/mL, unbuffered aqueous solution) permeated
0.75 mm dermatomed skin at a rate of 222.1±21.4 μg/cm2 per 24 h
while 51.2±8.6 μg/cm2 remained deposited on the skin. Overall,
8.2% of the applied dose was delivered within 24 h.
3.2. Antigen uptake is mainly mediated by Langerin negative dendritic
cells
As a next step, we investigated antigen uptake and transport to skin
draining lymph nodes (DLN) by ﬂow cytometric analysis of DLN DCs,
72 h after application of FITC labeled dextran to micropores. DCs in
DLNs were gated according to their high expression of MHC class II, fur-
ther separated into Langerin (CD207) positive and negative cells and an-
alyzed for uptake of FITC-dextran (Fig. 3A). With increasing pulse
numbers (corresponding to pore depth) we found increasing numbers
of FITC+ MHC IIhigh dendritic cells (Fig. 3B). Laserporation induced
higher levels of CD207+ CD11b− CD103− as well as CD207−
CD11b+DCs compared to subcutaneous injection whichmay represent
migrating LCs and dermal DCs, respectively that have just entered the
DLNs (Fig. 3C). However, whenwe investigated which cell types had ac-
tually taken up antigen, we found that predominantly CD207− cells
were positive for FITC(−dextran). Interestingly, antigen applied by s.c.
injection was taken up mainly by CD207− CD11b− DCs while
laserporation also induced antigen uptake by CD207− CD11b+DCs, in-
dicating that laserporation facilitates antigen uptake (and probably pre-
sentation) by CD11b-like or inﬂammatory DCs (Fig. 3D).
3.3. Antigen application via P.L.E.A.S.E.® activates antigen speciﬁc T cells
in DLNs
To assess antigen speciﬁc T cell activation via transcutaneous vaccina-
tion, OVA speciﬁc transgenic T cells (DO11.10 orOT-II for class II andOT-Ifor class I) were labeled with CFSE and adoptively transferred to synge-
neic recipient mice. To distinguish donor cells from recipient cells,
donor mice were of the CD45.1 haplotype while WT recipients were
CD45.2+. Application of OVA to laser-generated micropores resulted in
a dose-dependent proliferation of OVA-speciﬁc T cells (Fig. 4A, top
panel). Proliferation increasedwith the number of laser pulses andmax-
imal T-cell stimulation was usually achieved with 4–8 laser pulses
(supplementary Fig. 1). As expected, application of proteins to micro-
pores mainly activated CD4+ DO11.10 or OT-II T cells and to a much
lesser extent CD8+ OT-I cells (Fig. 4A). Although we cannot expect
that 100% of the epicutaneously applied antigen is taken up, TCI via mi-
cropores induced signiﬁcantly higher T cell proliferation compared to
s.c. injection (Fig. 4Amiddle panel) and similar levels compared to i.d. in-
jection of the same amount of antigen (supplementary Fig. 3). By selec-
tively ablating Langerin positive cells using Lang-DTR mice, we could
further show that activation of CD4+ OVA-transgenic T cells is, at least
in part, dependent on the presence of epidermal and/or dermal Lan-
gerin+ DCs (Fig. 4A middle panel).
To further investigate the immune proﬁle of antigen-speciﬁc T cells
after TCI vs. s.c immunization, we compared the expression proﬁle of
Fig. 4. T cell responses in skin draining lymph nodes. CD45.1+ OVA transgenic DO11.10,
OT-II, or OT-I T cells were transferred to syngeneic mice and T cell activation was assessed
by CFSE in vivo proliferation assay. A) Proliferation indices after application of different
doses (0.5, 5, or 50 μg) of OVA via laser-generated micropores (TCI) or subcutaneous injec-
tion (s.c.). In some groups, Langerin positive cells were depleted by application of diphtheria
toxin (LangDTR). B) Expression proﬁle of cellular markers in non-proliferating (grey, ﬁlled)
vs. proliferating cells after s.c. injection (black, solid) or TCI (black, dashed). Data are shown
for individual mice (n=3) in panel A or for pooled data from individual mice (n=3) in
panel B. * Pb0.05, ** Pb0.01.
Fig. 5. Cytokine proﬁles of adoptively transferred DO11.10 cells. OVA-speciﬁc DO11.10
cells were transferred to syngeneic mice and 100 μg OVA was applied by TCI or s.c. in-
jection. Subsequently, splenocytes were prepared and re-stimulated in vitro and cyto-
kines were measured in cell culture supernatants. Data are shown as means±SEM
(n=3). For TCI, 800 micropores with 1, 4, or 6 pulses delivered at 1.9 J/cm2 per
pulse were generated. * Pb0.05, ** Pb0.01.
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(Fig. 4B). Applying OVA to pores of different depth (1, 4 and 6 pulses)
did result in a very similar expression pattern of surface and intracellu-
lar markers (only the results for 6 pulses are shown). S.c. injection and
TCI induced nearly identical activation patterns. In all groups proliferat-
ing T cells signiﬁcantly (Pb0.001) downregulated CD45RB (and partly
also CD62L), indicative of a memory phenotype. However, down-
regulation of CD134 (OX-40, Pb0.001) at the same time suggests that
these T cells were not fully activated. Regarding Th1/Th2 differenti-
ation markers, we found no changes in the expression levels of the
key transcription factors T-bet (Th1) and Gata-3 (Th2). However,
surface expression of Tim-3 (Th1/Th17) was signiﬁcantly down-
regulated in proliferating T cells (Pb0.001), while Tim-1 (Th2) was
unaffected. With respect to regulatory T cell-associated markerswe found no induction of CD152+ (CTLA4), CD25, or FoxP3 in pro-
liferating T cells.3.4. Cytokine proﬁle of activated DO11.10 cells after TCI vs. s.c. injection
Splenocytes of vaccinated recipients were also re-stimulated in
vitro and the cytokine proﬁle was evaluated in cell culture super-
natants using a Th1/Th2/Th17 10-plex bead assay. Compared to
s.c. injection, TCI showed a trend towards increased Th2 polariza-
tion indicated by elevated levels of IL-4 and also enhanced IL-5
but also signiﬁcantly promoted IFN-γ secretion (Th1) and even
more prominently IL-17 and GM-CSF, both cytokines that can be at-
tributed to Th17 cell differentiation (Fig. 5). In general, Th1/Th2/
Th17 cytokine secretion increased with pore depth and reached a
maximum at 4 pulses; however, only IL-17 and GM-CSF signiﬁcant-
ly differed when comparing 1 pulse to 4 pulse application. While
these data implicate that TCI via laser-generated micropores can
induce profoundly different T cell polarization proﬁles compared
to s.c. injection, the Th17 phenotype found in adoptively trans-
ferred DO11.10 cells could not be conﬁrmed in the following in
vivo vaccination experiments.
Fig. 6. Immune responses against OVA in BALB/C LangDTR mice with or without deple-
tion of Langerin+ cells. One group was depleted of Langerin+ DCs by a single injection
of DT (1×DT) one day before the ﬁrst TCI. Immune responses were characterized by
ELISA (A), RBL assay (B) and cytokine secretion of in vitro re-stimulated splenocytes
determined by ELISPOT or from supernatants (C). Data are shown as means±SEM
(A) or as individual mice (B–C), n=5.
Fig. 7. Endogenous immune responses in BALB/c mice. A) Inﬂuence of different TLR ag-
onists on TCI induced IgE responses against bGal (n=3, serum dilution 1:100). B) IgE
and ELISPOT responses in mice immunized with bGal±10 μg CpG (n=3). C) Antibody
responses of mice immunized with recombinant Phl p 5±100 μg CpG (n=5). Data are
shown as means±SEM. Serum dilutions were 1:10,000 for IgG1/IgG2a, 1:100 for IgE,
or as indicated. * Pb0.05, ** Pb0.01, *** Pb0.001.
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Th1 responses by adjuvantation
In contrast to the previous experiments employing injected transgenic
T cells, analysis of the animal's own T cells, which had expanded after TCI,
elicited Th2 polarized immune responses. In these experiments, we im-
munized LangDTR mice with OVA applied to micropores generated with
6 pulses delivered at 1.9 J/cm2 per pulse. One group had been depleted
of Langerin+ DCs by a single injection of diphtheria toxin (DT) and a
non-depleted group served as control. Independent of DT administration,
both groups clearly mounted Th2 responses as indicated by high IgG1 to
IgG2a ratios (Fig. 6A), presence of IgE (Fig. 6B), as well as lack of IFN-γ,
and induction of IL-4 ELISPOTs. Of the 13 cytokines measured by Th1/
Th2/Th17/Th22multiplex bead assay, only IL-13, IL-22, and IL-6were sig-
niﬁcantly elevated compared to naïve mice. No Th1 or Th17 cytokines
were detectable (Fig. 6C).
The results obtained after immunization with OVA were conﬁrmed
using two further antigens (bGal, Phl p 5), different doses and variouspulse numbers. In all cases, clear Th2 responseswere elicited, as indicat-
ed by high IgG1 to IgG2a ratios. In the absence of the adjuvant CpG, the
same dose of Phl p 5 applied via TCI proved to be more immunogenic
compared to s.c. injection. Only TCI, but not s.c. injection induced anti-
gen speciﬁc IgE. However, these Th2 responses could be converted to
Th1 responses by co-application of TLR agonists. Of the tested agonists,
CpGweremost promising in suppressing TCI induced IgE responses and
inducing Th1 biased cellular responses, therefore further experiments
with two different antigens, namely bGal and Phl p 5, were performed
with CpG as adjuvant (Fig. 7).
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First described in 1998 as a new method to induce robust
immune responses via topical application of a vaccine antigen
together with an adjuvant [50], TCI has been a topic of intense inves-
tigation. Combining the advantages of needle free administration
with targeting a tissue rich in immunocompetent cells, this method
promises an attractive alternative to conventional vaccination
methods.
In our currentwork, we investigated the applicability of lasermicro-
poration using the P.L.E.A.S.E.® device for TCI. By sequential fractional
ablation, this device offers the unique opportunity to target different
layers of the skin, thereby addressing different cell types such as LCs
or dermal DCs. We could demonstrate that even in the mouse the stra-
tum corneum can be precisely removed without substantial damage to
the underlying epidermis (Fig. 1A). Alternatively deeper skin layers can
be targeted (Fig. 1B–D). In contrast to the study of Chen et al. [45], no
signs of thermal damage to the tissue surrounding the pores could be
detected (Fig. 1) and complete skin re-epithelialization was achieved
within 2 days (supplementary Fig. 1). Similar results were observed in
human volunteers [51] and during a clinical in vitro fertilization study,
demonstrating safety and clinical applicability of the device [44]. The
amount of antigen uptake and concomitant activation of T cells strongly
correlated with pore number and depth (Fig. 3B and supplemen-
tary Fig. 2). Although targeting the epidermis (1 pulse) showed a
trend towards increasing recruitment of CD207+ DCs, compared to
targeting the dermal compartment (8 pulses) (Fig. 3C), this was not
reﬂected by the distribution of DC subpopulations that actually had
acquired antigen (Fig. 3D). However, compared to s.c. injection, TCI
via laser microporation induced a different pattern of antigen pre-
senting DCs. While both modalities predominantly induced antigen
presentation byCD207−DCs, TCI favored the CD207− CD11b+subset
(Fig. 3D) specialized in CD4 T cell activation and humoral immunity
[52]. Although our analysis focused on MHC-IIhigh DCs, which
presumably represent migrating DCs from the periphery, the high per-
centage of FITC+MHC-IIhigh DCs after s.c. injection of FITC-dextran sug-
gests that some, if not themajority of the antigen had been taken up by
LN resident DCs that subsequently upregulated MHC-II [53]. This is
supported by the observation that the subcapsular sinus of the skin
draining LNs was ﬁlled with high amounts of FITC-dextran shortly
after s.c. injection, but not after TCI (data not shown).
It has been previously demonstrated that physical disruption of the
outermost skin layers results in secretion of pro-inﬂammatory cytokines
by skin keratinocytes and subsequent activation and migration of DCs
[12,54]. To investigate the immunogenicity of protein antigen without
adjuvant after TCI vs. s.c. injection, we ﬁrst used adoptively transferred
OVA speciﬁc T cells as a readout system, as this would facilitate detection
of activated T cells and characterization of their polarization. Additional-
ly, due to the short schedule of these experiments, complete ablation of
both, dermal as well as epidermal Langerin+ cells using LangDTR trans-
genic mice was possible [55]. Our data shows dose dependent activation
of CD4 T cells that was partly reliant on the presence of CD207+ DCs,
and alsoweak activation of OT-I (CD8+) cells (Fig. 4A). Although this in-
dicates some level of cross-presentation of exogenously acquired antigen
by DCs, similar experiments with bGal showed no induction of in vivo
CTLs (not shown). TCI induced superior CD4 activation compared to s.c.
injection of the same amount of antigen, although less antigen can be
expected to actually reach the draining LNs (compare Fig. 3B). This indi-
cates that either more potent subtypes of antigen-presenting DCs (ele-
vated levels of CD11b+ cells) were induced and/or that TCI elicited an
enhanced activation status of DCs migrating from the skin compared to
LN resident DCs that had taken up the antigen in the absence of a local
inﬂammatory stimulus.
Analysis of extracellular activation markers and intracellular polari-
zationmarkers on proliferating T cells revealed nomajor differences be-
tween TCI and s.c. injection (Fig. 4). TCI induced a more pronouncedinduction of a broad panel of cytokines in DO11.10 cells than s.c. injec-
tion, most notably IFN-γ (Th1) and IL-17 and GM-CSF, which has re-
cently been identiﬁed as a novel cytokine in the repertoire of Th17
cells [56]. On the cytokine level, we found a difference between
targeting the epidermis (1 pulse) and targeting dermal layers of the
skin (4 or 6 pulses) in that only targeting deeper layers of the skin
resulted in enhanced Th1/Th17 responses. These ﬁndings are in line
with other groupswho propose functional specializations of DC subsets
with regards to immune polarization and activation of T cell subsets
[57–59].
Surprisingly, the T helper polarization proﬁle of transferred and acti-
vated transgenic cells differed from that of the animal's own expanding T
cells after immunization. For the antigens tested, TCI resulted in clear Th2
biased immune responses, indicated by high IgG1 to IgG2a ratios,
induction of IL-4 and IL-13, and lack of Th1 and Th17 cytokines
(Fig. 6A, C and Fig. 7 B/C). This discrepancy can be explained by the arti-
ﬁcially high transgenic T cell precursor frequencies in the recipients,
which potentially lead to T cell competition for antigen presenting cells
resulting in weak or abnormal responses [60,61]. TCI but not s.c. immu-
nization induced antigen-speciﬁc IgE (Fig. 6B and Fig. 7 A, B, and C).
Also, no effect of Langerhans cell ablation could be observed. However,
due to the longer schedule of these studies, we could not ablate Lan-
gerin+ dermal DCs over the course of the experiment, due to unaccept-
able weight loss of mice repeatedly receiving DT. Therefore, in this
setting, only epidermal Langerhans cells were absent over the entire
course of the experiment, whereas dermal Langerin+ DCs quickly
repopulate the skin [62]. Together this suggests that epidermal
Langerhans cells are dispensable for TCI-induced Th2 responses, while
dermal Langerin+ DCs contribute at least partly to TCI-induced immu-
nogenicity. Again, in the absence of adjuvant, TCI proved to be more po-
tent than s.c. injection (Fig. 6C). It has been previously shown that barrier
disruption of skin leads to promotion of Th2 type immune responses
[63], and uptake of allergen via barrier-disrupted skin is discussed as a
major source of allergic sensitization [64,65]. However, by application
of suitable adjuvants, such as CpGODN, this Th2 phenotype could be suc-
cessfully converted towards a balanced Th1/Th2 response, with concom-
itant suppression of TCI induced IgE (Fig. 7B and C). This is in line with
data showing that CpG ODN prevented Th2mediated skin inﬂammation
in a model of AD and also could reverse established eosinophilic inﬂam-
mation [66].
In summary, we demonstrated for the ﬁrst time that TCI via laser
microporation is a potent method for inducing immune responses via
the skin. The formation of precise micropores of deﬁned number and
depth allow for high levels of antigen uptake and generation of immune
responses equal or higher, compared to those induced by s.c. injection
of antigen. Our data indicate that targeting different layers of the skin
has the potential to bias different T cell polarization patterns. Through
adjuvantation, the immune phenotype can be further modulated, mak-
ing laser microporation with the P.L.E.A.S.E. ® device a versatile plat-
form for vaccine delivery.Acknowledgments
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